Stock RXRX RECURSION PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Recursion Pharmaceuticals, Inc.

Equities

RXRX

US75629V1044

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
8.12 USD +3.57% Intraday chart for Recursion Pharmaceuticals, Inc. +10.48% -17.65%
04-18 Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing MT
04-16 Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer MT

Business Summary

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.

Number of employees: 500

Sales per Business

USD in Million2022Weight2023Weight Delta
Drug Discovery
100.0 %
40 100.0 % 45 100.0 % +11.88%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
40 100.0 % 45 100.0 % +11.88%

Managers

Managers TitleAgeSince
Chistopher Gibson FOU
 Founder 41 04/11/13
Blake Borgeson FOU
 Founder 42 04/11/13
Dean Li FOU
 Founder 62 04/11/13
Tina Larson PSD
 President 49 30/06/18
Michael Secora DFI
 Director of Finance/CFO 41 29/02/20
Ganesh Kumar Jagannathan CTO
 Chief Tech/Sci/R&D Officer - -
Jordan Christensen CTO
 Chief Tech/Sci/R&D Officer - 15/08/21
Benjamin Mabey CTO
 Chief Tech/Sci/R&D Officer 41 28/02/17
Laura Schaevitz CTO
 Chief Tech/Sci/R&D Officer - -
David Mauro CTO
 Chief Tech/Sci/R&D Officer 59 31/05/23

Members of the board

Members of the board TitleAgeSince
Robert Hershberg BRD
 Director/Board Member 61 19/03/20
Ramon Chavez Márquez CHM
 Chairman 60 31/03/20
Dean Li FOU
 Founder 62 04/11/13
Blake Borgeson FOU
 Founder 42 04/11/13
Zachary Bogue BRD
 Director/Board Member 48 31/07/18
Zavain Dar BRD
 Director/Board Member 35 31/08/16
Chistopher Gibson FOU
 Founder 41 04/11/13
Terry-Ann Burrell BRD
 Director/Board Member 47 31/03/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 10 7,509,871 0 0 91.44 %
Stock B 1 230,107,332 217,267,089 ( 94.42 %) 0

Shareholders

NameEquities%Valuation
ARK Investment Management LLC
11.80 %
24,587,561 11.80 % 245 M $
Baillie Gifford & Co.
11.61 %
24,179,504 11.61 % 241 M $
ARK Investment Management LLC
11.08 %
23,076,052 11.08 % 230 M $
Vanguard Fiduciary Trust Co.
7.521 %
15,665,210 7.521 % 156 M $
Mubadala Investment Co. (Investment Company)
6.235 %
12,985,927 6.235 % 129 M $
STATE STREET CORPORATION
5.834 %
12,151,646 5.834 % 121 M $
BlackRock Advisors LLC
5.391 %
11,229,466 5.391 % 112 M $
Fidelity Management & Research Co. LLC
5.232 %
10,897,287 5.232 % 109 M $
Kinnevik AB (Investment Company)
4.996 %
10,405,668 4.996 % 104 M $
SUMITOMO MITSUI TRUST HOLDINGS, INC.
4.975 %
10,362,803 4.975 % 103 M $
NameEquities%Valuation
Chistopher Gibson
78.83 %
7,463,371 78.83 % 74 M $

Company contact information

Recursion Pharmaceuticals, Inc.

41 South Rio Grande Street

84101, Salt Lake City

+

http://www.recursion.com
address Recursion Pharmaceuticals, Inc.(RXRX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Recursion Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
8.12 USD
Average target price
13 USD
Spread / Average Target
+60.10%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
RECURSION PHARMACEUTICALS, INC. Stock Recursion Pharmaceuticals, Inc.
-17.65% 1.93B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+0.64% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-8.42% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RXRX Stock
  4. Company Recursion Pharmaceuticals, Inc.